Clinical Trial Update: Efficacy-Safety-Immunogenicity Study of CBT124&EU-sourced Avastin® in Stage 4 NSCLC [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating the efficacy, safety, and immunogenicity of CBT124 with EU-sourced Avastin (bevacizumab) in stage 4 non-small cell lung cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Avastin (bevacizumab)
• CBT124

Snippet

Sponsor: Cipla BioTec Pvt. Ltd. | Conditions: Non-Small Cell Lung Carcinoma | Phase 3 | Status: UNKNOWN